Genfit SA (GNFTF)
OTHER OTC:GNFTF
GNFTF Stock Chart & Stats
$9.32
$0.10(2.91%)
At close: 4:00 PM EST
$9.32
$0.10(2.91%)
Day’s Range― - ―
52-Week Range$2.95 - $10.88
Previous CloseN/A
Volume2.00K
Average Volume (3M)0.00
Market Cap
$505.97M
Enterprise Value$490.10M
Total Cash (Recent Filing)$101.09M
Total Debt (Recent Filing)$150.69M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Sep 30, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding50,080,223
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-11.11
Price to Sales (P/S)4.01
P/FCF Ratio-9.84
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue7.26
Enterprise Value/Gross Profit27.91
Enterprise Value/Ebitda-80.95
Forecast
1Y Price Target
$17.53Price Target Upside88.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.23
Revenue Forecast (FY)$94.73M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Model: Diagnostics Plus PartnershipsA mixed model of product commercialization plus licensing/collaboration revenues provides durable, multi-channel cash generation potential. Product sales can create recurring revenue while partnerships offer upfront, milestone and royalty streams that reduce reliance on a single source over the medium term.
Proprietary Technology And Focused Therapeutic NicheOwnership of proprietary diagnostic/therapeutic technology and a clear focus on metabolic and liver diseases create structural advantages: specialized expertise, potential clinical differentiation, and licensing or partnership leverage that support long-term commercial and R&D value creation.
Meaningful 2025 Revenue ReboundA significant top-line rebound signals improving market adoption or successful commercialization execution, which can form the basis for scaling operations and future margin recovery if cost discipline and cash generation accompany continued revenue traction.
Bears Say
Negative Shareholders' Equity And Weakened CapitalizationNegative equity indicates accumulated losses have eroded the capital base, reducing financial flexibility and increasing refinancing risk. This structural weakness constrains investment capacity, may impair partner confidence, and elevates the importance of external funding or turnaround in profitability.
Renewed Negative Operating And Free Cash FlowReturn to negative operating and free cash flow reintroduces persistent funding needs and reliance on external financing. Ongoing cash burn threatens runway, increases dilution or debt risk, and limits the company’s ability to sustainably fund commercialization and R&D investments without new capital.
Profitability Deterioration And Volatile EarningsSharp swings from profit to large losses indicate earnings instability and weak margin sustainability. Persistent volatility undermines long-term planning, complicates partner and investor confidence, and may force reactive cost measures that impair growth execution if profitability isn't stabilized.
Genfit News
GNFTF FAQ
What was Genfit SA’s price range in the past 12 months?
Genfit SA lowest stock price was $2.95 and its highest was $10.88 in the past 12 months.
What is Genfit SA’s market cap?
Genfit SA’s market cap is $505.97M.
When is Genfit SA’s upcoming earnings report date?
Genfit SA’s upcoming earnings report date is Sep 30, 2026 which is in 169 days.
How were Genfit SA’s earnings last quarter?
Genfit SA released its earnings results on Apr 02, 2026. The company reported -$0.035 earnings per share for the quarter, the consensus estimate of -$0.035 by $0.
Is Genfit SA overvalued?
According to Wall Street analysts Genfit SA’s price is currently Undervalued.
Does Genfit SA pay dividends?
Genfit SA does not currently pay dividends.
What is Genfit SA’s EPS estimate?
Genfit SA’s EPS estimate is -0.02.
How many shares outstanding does Genfit SA have?
Genfit SA has 50,080,223 shares outstanding.
What happened to Genfit SA’s price movement after its last earnings report?
Genfit SA reported an EPS of -$0.035 in its last earnings report, expectations of -$0.035. Following the earnings report the stock price went up 0.806%.
Which hedge fund is a major shareholder of Genfit SA?
Currently, no hedge funds are holding shares in GNFTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genfit SA
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
GNFTF Stock 12 Month Forecast
Average Price Target
$17.53
▲(88.09% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
― Other Institutional Investors
99.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---